Special Issue

Drug Delivery in Chronic Inflammatory Respiratory Diseases

Message from the Guest Editors

I am putting together a Special Issue titled "Drug **Delivery in Chronic Inflammatory Respiratory** Diseases" that I think may be of interest to you. I invite you to submit a manuscript for consideration and possible publication in this Special Issue of Pharmaceutics. Chronic inflammatory diseases of the lung are a major health burden worldwide, and the need for better treatments and mechanisms to deliver these therapeutics are in high demand. This Special Issue aims to highlight research into new drug targets for diseases such as asthma, fibrosis, and COPD, among others, as well as novel methods for the delivery and manufacture of these therapies, including nanoparticle delivery via extracellular vesicles. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: novel drug discovery, delivery mechanisms (including extracellular vesicle delivery), newly identified targets for drug design, and therapy/treatments for chronic lung inflammation. I look forward to receiving your contributions. Dr. Kristopher R. Genschmer

Guest Editors

Dr. Kristopher Genschmer

DOM-Pulmonary, Allergy, and Critical Care Medicine, 1720 2nd Ave South, BBRB 830, Birmingham, AL 35294-0006, USA

Dr. Camilla Margaroli

Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA

Deadline for manuscript submissions

closed (31 July 2023)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/137417

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

